Inhibrx, Inc. Common Stock
INBX
INBX was delisted on the 29th of May, 2024.
108 hedge funds and large institutions have $692M invested in Inhibrx, Inc. Common Stock in 2023 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 37 increasing their positions, 34 reducing their positions, and 23 closing their positions.
4,404% more call options, than puts
Call options by funds: $4.19M | Put options by funds: $93K
9% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 34
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
7% less funds holding
Funds holding: 116 → 108 (-8)
22% less capital invested
Capital invested by funds: $886M → $692M (-$194M)
35% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 23
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
+$40.7M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
+$7.31M |
| 3 |
PA
Perceptive Advisors
New York
|
+$7.01M |
| 4 |
Renaissance Technologies
New York
|
+$4.97M |
| 5 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
+$3.75M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$18.6M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$11.9M |
| 3 |
State Street
Boston,
Massachusetts
|
-$10M |
| 4 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
-$4.6M |
| 5 |
TCM
Tybourne Capital Management
Hong Kong
|
-$2.36M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
126
Qube Research & Technologies (QRT)
London,
United Kingdom
| – | -$202K | -8,207 | Closed |
|
127
Amundi
Paris,
France
| – | -$11K | -465 | Closed |
|
128
Allspring Global Investments
Charlotte,
North Carolina
| – | -$4.9K | -199 | Closed |
|
|
LC
129
Lindbrook Capital
Calabasas,
California
| – | -$1.82K | -74 | Closed |
|
|
EI
130
Ellevest Inc
New York
| – | -$25 | -1 | Closed |
|
INBX Hedge Fund Activity: Q1 2023 in Review
108 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Inhibrx, Inc. Common Stock (INBX) for Q1 2023, worth a combined $692M — down 22% from $886M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of INBX and 15 opened new positions — a net loss of 8 holders — while 34 trimmed existing stakes and 37 added.
The largest buyer was Capital Research Global Investors, opening a new position worth an estimated $40.7M. The largest seller was Wellington Management Group, cutting an estimated $18.6M.
- 108 institutional investors held Inhibrx, Inc. Common Stock (INBX) as of Q1 2023, down from 116 in Q4 2022.
- Funds reported $692M of Inhibrx, Inc. Common Stock stock for Q1 2023, down 22% quarter-over-quarter.
- 15 funds opened new Inhibrx, Inc. Common Stock positions in Q1 2023 and 23 closed out, a net change of -8 holders.
- The largest Inhibrx, Inc. Common Stock buyer in Q1 2023 was Capital Research Global Investors, an estimated $40.7M added.
- The largest Inhibrx, Inc. Common Stock seller in Q1 2023 was Wellington Management Group, an estimated $18.6M sold.
Based on aggregated 13F filings for Q1 2023.